Shares of Aytu Bioscience (NASDAQ:AYTU) opened at 3.40 on Monday. The firm’s market capitalization is $17.24 million. The stock has a 50 day moving average of $3.64 and a 200 day moving average of $4.79. Aytu Bioscience has a 52-week low of $3.01 and a 52-week high of $57.00.
Aytu Bioscience Company Profile
Aytu Bioscience, Inc, formerly Rosewind Corporation, is a healthcare company. The Company is focused on developing treatments for urological and related conditions. The Company’s pipeline of products includes Zertane, and Zertane and a phosphodiesterase type 5 (PDE-5). The Company is conducting Phase III clinical development for its lead therapeutic candidate Zertane, an orally disintegrating tablet (ODT) formulated for the treatment of premature ejaculation (PE).
Receive News & Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.